-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

501 Novel CoupledCARTM Technology for Treating Colorectal Cancer

Program: Oral and Poster Abstracts
Type: Oral
Session: 801. Gene Editing, Therapy and Transfer I
Hematology Disease Topics & Pathways:
Biological, Therapies, CAR-Ts, immune cells, gene therapy, immunotherapy, infusion
Sunday, December 6, 2020: 3:00 PM

Lei Xiao, PhD1, Song Li2*, Chengfei Pu1*, Zhiyuan Cao1*, Xinyi Yang3*, Ning Li3*, Youli Luo4*, Haiyan Zhao5*, Hang Yang1*, Xi Huang1*, Xiaogang Shen1*, Xiuwen Wang2*, Yongping Song3*, Junjie Mao4*, Pengfei Pang4*, Zhao Wu1*, Victor Lu, PhD6* and Qun Hu5*

1Innovative Cellular Therapeutics, Shanghai, China
2Shandong University, Jinan, China
3Zhengzhou University, Zhengzhou, China
4SUN YAT-SEN University, Guangzhou, China
5Inner Mongolia Medical University, Neimenggu, China
6Innovative Cellular Therapeutics, Inc, Rockville, MD

Chimeric antigen receptor (CAR) T cell therapy has made significant progress in the treatment of blood cancers such as leukemia, lymphoma, and myeloma. However, the therapy faces many challenges in treating solid tumors. These challenges include physical barriers, tumor microenvironment immunosuppression, tumor heterogeneity, target specificity, and limited reactive cell expansion in vivo.

Conventional CAR T cell therapy has thus far shown weak cell expansion in solid tumor patients and achieved little or no therapeutic responses. Here, we developed CAR T cells based on a novel CoupledCAR® technology to treat solid tumors. In contrast to conventional CAR T cells, CoupledCAR T cells significantly improved the expansion of the CAR T cells in vivo and enhanced the CAR T cells’ migration ability and resistance to immunosuppression by the tumor microenvironment. The enhanced migration ability and resistance allow the CAR T cells to infiltrate to tumor tissue sites and increase anti-tumor activities.

Specifically, we engineered CoupledCAR T cells with lentiviral vectors encoding an anti-GCC (guanylate cyclase 2C) CAR molecule. Furthermore, anti-GCC CAR T cells showed anti-tumor activities in vitro and in vivo experiments.

To verify the safety and efficacy of CoupledCAR T cells for treating solid tumors, we conducted several clinical trials for different solid tumors, including seven patients with colorectal cancer. These seven patients failed multiple rounds of chemotherapy and radiotherapy. In the clinical trial, the patients were infused with autologous anti-GCC CoupledCAR T cells range from 4.9×10^5/kg to 2.9×10^6/kg. All patients using anti-GCC CoupledCAR T cells showed rapid expansion of CoupledCAR T cells and killing of tumor cells. Specifically, we observed that CoupledCAR T cells expanded significantly in the patients and infiltrated tumor tissue sites, demonstrating enhanced anti-tumor activities. PET/CT showed significant tumor shrinkage and SUV max declined, and the ongoing responses were monitored. Patient 3 achieved complete response and the best overall response rate (ORR, include complete remission, complete metabolic response, partial response, and partial metabolic response.) was 71.4% (5/7), complete remission (CR) rate was 14.3% (1/7).

The clinical data demonstrated that CoupledCAR T cells effectively expanded, infiltrated tumor tissue sites, and kill tumor cells in patients with colorectal cancer. We used immunotherapy to achieve complete remission in patients with advanced colorectal cancer for the first time. We are recruiting more colorectal cancer patients to further test the safety and efficacy of anti-GCC CoupledCAR T cells. Since our CoupledCAR® technology is a platform technology, we are expanding it to treat other solid tumors using different target tumor markers .

Disclosures: Xiao: Innovative Cellular Therapeutics: Other: stockholder.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH